An infant with ETV6-NTRK3 fusion-positive congenital infantile fibrosarcoma and delayed response to conventional chemotherapy avoiding the need for TRK inhibition. (2020)

First Author: Vedi A
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/pbc.28628

PubMed Identifier: 32748441

Publication URI: http://europepmc.org/abstract/MED/32748441

Type: Journal Article/Review

Volume: 67

Parent Publication: Pediatric blood & cancer

Issue: 10

ISSN: 1545-5009